Keenova

Keenova is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics targeting the Hippo signaling pathway. The company's research centers on the YAP/TAZ-TEAD transcriptional complex, which plays a critical role in cell proliferation and is frequently dysregulated in various cancers. Keenova's lead program, KNV-001, is a potent TEAD inhibitor designed to treat solid tumors with NF2 mutations or other Hippo pathway alterations. By addressing these specific genetic drivers, the company aims to provide precision medicine options for patients with high unmet medical needs, including those with mesothelioma and meningioma. Keenova operates with a global vision, maintaining research and development facilities in both China and the United States.